Quantcast

Latest Nuvo Research Inc. Stories

2014-09-08 08:29:52

MISSISSAUGA, ON, Sept. 8, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has reached a full settlement with Mallinckrodt Inc. of Nuvo's claims and Mallinckrodt's counterclaim relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid(®) and Pennsaid 2% in the United States. Under the terms of the settlement agreement, Mallinckrodt will return...

2014-09-04 08:30:05

MISSISSAUGA, ON, Sept. 4, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that John London, the Company's President and Co-Chief Executive Officer will be providing a corporate update at the Rodman & Renshaw Global Investment Conference on Tuesday, September 9, 2014 in New York. A copy of the presentation will be available on the Company's website at...

2014-09-03 08:33:19

- Results Expected Q1 2015 - MISSISSAUGA, ON, Sept. 3, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has completed enrolment in its Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. The Company expects the trial to be completed in late 2014 with top-line results anticipated in the first...

2014-07-30 16:30:01

MISSISSAUGA, ON, July 30, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the second quarter ended June 30, 2014. WF10 Phase 2 Clinical Trial Update The enrolment for the Phase 2 WF10 clinical trial for the treatment of allergic rhinitis commenced in March 2014 and to-date, 121 patients have been enrolled at 15 sites in...

2014-06-11 16:27:04

MISSISSAUGA, ON, June 11, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that at its 2014 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 30, 2014 were elected as directors of the Company. The detailed results of the votes by proxy are as follows: Director Nominees...

2014-05-29 08:29:40

MISSISSAUGA, ON, May 29, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that a third party has received U.S. Food and Drug Administration (FDA) approval to market and sell a topical diclofenac sodium 1.5% solution in the United States. The product is a generic version of Nuvo's PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID 1.5%). Mallinckrodt Inc. (NYSE:MNK)...

2014-04-23 08:31:25

MISSISSAUGA, ON, April 23, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced a collaboration involving Ferndale Laboratories, Inc. (Ferndale) and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer (MMPE(TM)) technology. "This...

2014-04-01 08:28:19

MISSISSAUGA, ON, April 1, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), (the "Company"), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, is pleased to announce the closing of a non-brokered private placement (the "Private Placement"), pursuant to which an aggregate of 1,390,000 units of the Company were issued at a price of $2.25 per unit, raising gross proceeds of approximately $3,127,500. Each Unit consists of one common share...

2014-02-20 16:26:45

MISSISSAUGA, ON, Feb. 20, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the fourth quarter and year ended December 31, 2013. "In 2013 and early 2014, we significantly advanced our three FDA approved commercial products that will contribute to Nuvo revenues. Pennsaid 2% was approved and launched in the U.S., Pliaglis was...

2014-02-10 08:26:43

MISSISSAUGA, ON, Feb. 10, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced the U.S. commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) by its U.S. commercial licensee Mallinckrodt (NYSE:MNK). PENNSAID 2% is the first twice per day topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the United States for the...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'